149 related articles for article (PubMed ID: 36031014)
1. The influence on the oral bioavailability of solubilized and suspended drug in a lipid nanoparticle formulation: In vitro and in vivo evaluation.
Elbrink K; Van Hees S; Roelant D; Loomans T; Holm R; Kiekens F
Eur J Pharm Biopharm; 2022 Oct; 179():1-10. PubMed ID: 36031014
[TBL] [Abstract][Full Text] [Related]
2. Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.
Liu Y; Salituro GM; Lee KJ; Bak A; Leung DH
AAPS PharmSciTech; 2015 Oct; 16(5):1091-100. PubMed ID: 25690735
[TBL] [Abstract][Full Text] [Related]
3. Modification of microenvironmental pH of nanoparticles for enhanced solubility and oral bioavailability of poorly water-soluble celecoxib.
Ran Woo M; Bak YW; Cheon S; Suk Kim J; Hun Ji S; Park S; Woo S; Oh Kim J; Giu Jin S; Choi HG
Int J Pharm; 2024 Jun; 659():124179. PubMed ID: 38692498
[TBL] [Abstract][Full Text] [Related]
4. Optimized Nanoparticles for Enhanced Oral Bioavailability of a Poorly Soluble Drug: Solid Lipid Nanoparticles Versus Nanostructured Lipid Carriers.
Darwish MKM; El-Enin ASMA; Mohammed KHA
Pharm Nanotechnol; 2022; 10(1):69-87. PubMed ID: 35142275
[TBL] [Abstract][Full Text] [Related]
5. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
6. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
Banerjee S; Pillai J
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
[No Abstract] [Full Text] [Related]
7. Improving in vivo oral bioavailability of a poorly soluble drug: a case study on polymeric versus lipid nanoparticles.
Rassu G; Obinu A; Serri C; Piras S; Carta A; Ferraro L; Gavini E; Giunchedi P; Dalpiaz A
Drug Deliv Transl Res; 2023 Apr; 13(4):1128-1139. PubMed ID: 36509967
[TBL] [Abstract][Full Text] [Related]
8. Preparation and evaluation of celecoxib-loaded proliposomes with high lipid content.
Jeon D; Kim KT; Baek MJ; Kim DH; Lee JY; Kim DD
Eur J Pharm Biopharm; 2019 Aug; 141():139-148. PubMed ID: 31150807
[TBL] [Abstract][Full Text] [Related]
9. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations.
Yasmin R; Tan A; Bremmell KE; Prestidge CA
J Pharm Sci; 2014 Sep; 103(9):2950-2959. PubMed ID: 24585389
[TBL] [Abstract][Full Text] [Related]
10. Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate.
Yasir M; Gaur PK; Puri D; Shehkar P; Kumar SS
Curr Drug Deliv; 2018; 15(6):818-828. PubMed ID: 28545354
[TBL] [Abstract][Full Text] [Related]
11. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide.
Gonçalves LM; Maestrelli F; Di Cesare Mannelli L; Ghelardini C; Almeida AJ; Mura P
Eur J Pharm Biopharm; 2016 May; 102():41-50. PubMed ID: 26925503
[TBL] [Abstract][Full Text] [Related]
12. Effective in-vivo utilization of lipid-based nanoparticles as drug carrier for carvedilol phosphate.
Chakraborty S; Shukla D; Vuddanda PR; Mishra B; Singh S
J Pharm Pharmacol; 2011 Jun; 63(6):774-9. PubMed ID: 21585374
[TBL] [Abstract][Full Text] [Related]
13. Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapad
Ilie AR; Griffin BT; Brandl M; Bauer-Brandl A; Jacobsen AC; Vertzoni M; Kuentz M; Kolakovic R; Holm R
Eur J Pharm Sci; 2020 Sep; 152():105452. PubMed ID: 32622980
[TBL] [Abstract][Full Text] [Related]
14. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
15. Fabrication of Niclosamide loaded solid lipid nanoparticles: in vitro characterization and comparative in vivo evaluation.
Rehman MU; Khan MA; Khan WS; Shafique M; Khan M
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1926-1934. PubMed ID: 29113501
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin.
Liu Y; Wang L; Zhao Y; He M; Zhang X; Niu M; Feng N
Int J Pharm; 2014 Dec; 476(1-2):169-77. PubMed ID: 25280882
[TBL] [Abstract][Full Text] [Related]
17. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process.
Ha ES; Choo GH; Baek IH; Kim MS
Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
20. Selection of oral bioavailability enhancing formulations during drug discovery.
Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
